94 results about "Thymine" patented technology

The invention discloses an information storage method based on DNA (deoxyribonucleic acid) coding, which comprises the following steps: converting digital information to be stored into a quaternary code, converting the quaternary code into a DNA sequence consisting of adenine A, cytosine C, guanine G and thymine T according to a preset mapping rule, and expressing an additional information dimension by using a chemical modification state of a nucleotide pair; inserting error detection and correction codes in the DNA sequence every a predetermined number of basic group positions, segmenting the encoded DNA sequence into a plurality of fragments with the length of 100-150bp, and adding a specific recognition sequence and an index marker at two ends of each fragment; a reversible thermosensitive response DNA nanostructure is used as a carrier, DNA fragments are selectively combined to the carrier, and hierarchical storage and rapid retrieval of information are realized through a temperature gradient control system; the DNA storage information density can be remarkably improved, the service life of DNA storage can be remarkably prolonged, and a novel technical path is provided for large-scale, long-term and safe molecular information storage.

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

Described herein is a topical formulation. The topical formulation includes a thymine-thymine compound including Formula (1) and a solvent system. The topical formulation includes about 0.01 wt% to about 10 wt% of the thymine-thymine compound, based on total weight of the formulation. A method of preparing the topical formulation is also provided.

The invention discloses a synthesis method of 2 '-fluoro-2'-deoxyguanosine. According to the method, thymine nucleoside phosphorylase and purine nucleoside phosphorylase are used as biocatalysts, and 2 '-fluoro-2'-deoxyuridine and guanine are used as substrates to synthesize the 2 '-fluoro-2'-deoxyguanosine. Compared with a chemical method, the production cost is greatly reduced; meanwhile, the synthesis method can effectively solve the problem that the product is difficult to separate.

A phosphorothioate-containing RNA molecule that includes the nucleotide sequence: 5'-NCCCUGGUGGUCUAGUGGUUAGGAUUCGGCGC-3' (SEQ ID NO: 1), where N is uracil or thymine, is provided. The RNA molecule can include one or more phosphorothioate bonds between nucleic acid residues in one or more pairs (e.g., between nucleic acid residues in each pair) of consecutive nucleic acid residues within SEQ ID NO: 1. The RNA molecule and compositions thereof find use in treating muscle disorders, such as muscular dystrophy, heart conditions, such as heart failure or myocardial infarction, and / or conditions associated with inflammation and / or fibrosis.

The present invention provides novel triazolopyrimidines derived from nucleobase thymine, and methods of producing the same, as well as various biologically active substances obtained by the methods, particularly antitumor agents. The triazolopyrimidine compounds represented by the following formulas (I) to (VIII) (wherein R represents a hydrogen atom, an alkyl group, or an aryl group) and methods of producing the same.

Provided are compositions, methods, and systems for DNA pyrimidine-base editing. In some embodiments, provided are engineered thymine-modifying polypeptides or engineered cytosine-modifying polypeptides comprising a variant of a uracil-DNA glycosylate (UNG). In some embodiments, provided are such engineered polypeptides and a DNA recognition domain, which are configured to target a nucleic acid for excision. Also provided herein are nucleic acid encoding the polypeptides described herein, additional components useful for editing, such as sgRNA, kits, medicines, composition, and method of use thereof.

The present invention relates to the field of data storage, and discloses a DNA-based dynamic balancing system, a data storage method, and a decoding method. During the process of encoding the first data to obtain a DNA molecular chain, various constraints are added to the first address and the second address, enabling the encoded data to be read efficiently and accurately. For example, the Hamming distance between the first address and the second address is greater than or equal to half of the length of the first address, reducing the possibility of address selection errors during reading; the prefix of the first address is different from the prefix of the second address and the suffix of the second address, avoiding the possibility of matching errors during the reading process; the content of guanine and cytosine in the prefix of each primer accounts for a preset ratio of the total content of guanine, cytosine, adenine, and thymine contained in the primer, resulting in high accuracy when sequencing is required to read the encoded data in advance.

Described herein are methods of modifying or editing a target nucleic acid such as methods that edit adenine to cytosine, thymine, or guanine. Compositions and systems for modifying or editing a target nucleic acid are also described. Methods, compositions and systems described herein may be used for generating allelic diversity.

The application discloses a method for producing deoxythymidine triphosphate by using a recombinant strain, and comprises the following steps: step 1: using a CRISPR / Cas9-mediated gene editing method to perform targeted modification on an E. coli genome, and the targeted modification comprises the following contents: a. knocking out a nucleoside triphosphate pyrophosphatase gene (mazG / yhdE) to block a path of degrading dTTP into dTMP; b. knocking out a nucleotide nucleosidase gene (ppnN) to block a path of degrading dTMP into thymine; and c. knocking out a nucleotidase gene (yfbR / yfdR / ushA / umpH / umpG / yjjG) to block a path of degrading dTMP into dT. The application provides a method for producing deoxythymidine triphosphate by using a recombinant strain, and the conversion rate of the method reaches 80% to 90%, and after ion exchange chromatography purification, the purity can reach more than 99%.

The present invention discloses an information storage method based on DNA coding. The method comprises the following steps: converting digital information to be stored into a quaternary code, and converting the quaternary code into a DNA sequence consisting of adenine A, cytosine C, guanine G, and thymine T according to a preset mapping rule, and using the chemical modification state of the nucleotide pairs to represent an additional information dimension; inserting error detection and correction codes at every predetermined number of base positions in the DNA sequence, dividing the encoded DNA sequence into multiple fragments of 100-150 bp in length, and adding specific recognition sequences and index markers at both ends of each fragment; utilizing a reversibly thermoresponsive DNA nanostructure as a carrier, selectively binding the DNA fragments to the carrier, and realizing hierarchical storage and rapid retrieval of information through a temperature gradient control system; the present invention can significantly improve the information density and lifespan of DNA storage, and provides a new technical path for large-scale, long-term, and secure molecular information storage.

The invention provides nucleic acid base composite nano-particles and a preparation method thereof. The preparation method comprises the following steps: taking PDMA and an acrylate adenine monomer as raw materials, carrying out polymerization to obtain a diblock polymer, taking the diblock polymer and a coumarin monomer as raw materials, carrying out polymerization to obtain PA, and assembling the PA into a nucleated cross-linked nano-micelle; pDMA and an acrylate thymine monomer are used as raw materials and polymerized to obtain a block polymer, and the block polymer is assembled into the nano-micelle; and mixing the core cross-linked nano-micelles with the nano-micelles, and interacting to obtain the composite nano-particles. According to the preparation method disclosed by the invention, the core-crosslinked nano-micelle containing adenine is constructed, and the nano-micelle has poly (N, N-dimethylacrylamide) with a hydrophilic block, and the poly (N, N-dimethylacrylamide) can stably exist in an aqueous solution; and mixing the core-crosslinked nano-micelles with the nano-micelles to obtain the composite nano-particles through biologically excited nuclear-base interaction.

The invention discloses application of a methyltransferase mutant and deaminase in DNA methylation single base resolution sequencing, and relates to the technical field of gene sequencing. On the basis of a methyltransferase mutant M.MedI-N377K, cytosine at a CG site in DNA (Deoxyribonucleic Acid) can be specifically recognized, and carboxymethyl of carboxyl-S-adenosine-L-methionine (caSAM) is transferred to a C5 site of C in the CG, so that the 5-carboxymethyl cytosine is generated. 5-methylcytosine can be subjected to deamination by deaminase to form thymine, and the thymine is paired with adenine in subsequent PCR amplification; and 5cam C can resist deamination of A3A and is paired with guanine in subsequent PCR (Polymerase Chain Reaction), and 5mC is read as T and C is read as C in a subsequent Sanger sequencing result of an amplification product, so that C and 5mC in DNA (Deoxyribonucleic Acid) are distinguished. The method disclosed by the invention is high in sensitivity, good in specificity and simple to operate, does not involve hydrosulfite treatment, and can be used for carrying out positioning analysis on 5mC in a biological sample under a single-base resolution ratio.

The invention discloses a resolution positioning analysis method for an 8-oxo-2 '-deoxyguanine modified single base in DNA (Deoxyribonucleic Acid), and belongs to the technical field of biology. The method comprises the following steps: firstly, extracting genome DNA, ultrasonically breaking, then denaturing into single-stranded DNA, and enriching the single-stranded DNA containing 8-oxo-dG by using an antibody; adding a 3 ' / 5' universal sequencing joint to the enriched single-stranded DNA; fixing the amino-modified extension primer to the carboxyl-modified magnetic bead to obtain an extension primer fixed by the carboxyl-modified magnetic bead; extension is carried out through an extension primer fixed by a carboxyl modified magnetic bead, and 8-oxo-2'deoxyguanine-thymine in DNA polymerase mediation enrichment single-stranded DNA is converted, so that a primer extension product fixed on the magnetic bead is obtained; purifying a primer extension product fixed on the magnetic beads; and carrying out PCR amplification on the primer extension product, and carrying out enzyme digestion or sequencing analysis. According to the method, the reaction system is mild, the defect that DNA oxidation modification is possibly artificially introduced in an existing chemical labeling method is avoided, and Ggt is passed; t conversion is carried out, so that the 8-oxo-dG can be modified, positioned and analyzed more directly and accurately.

Adapters are provided. An adapter includes at least one first sub-adapter. Each first sub-adapter includes: a first nucleotide single strand and a second nucleotide single strand, the first nucleotide single strand being complementarily paired with the second nucleotide single strand; and a first nucleotide single strand segment, the first nucleotide single strand segment being ligated to an end of the first nucleotide single strand or an end of the second nucleotide single strand. The first nucleotide single strand segment includes at least one random base and at least one adenine (A) base. Each random base is any one of an A base, a cytosine (C) base, a guanine (G) base and a thymine (T) base.

A system for analyzing biological components in a biological sample, wherein the system comprises a planar surface, and wherein the system is configured to perform a procedure comprising: (a) arranging a spatially connected biological sample adjacent to the planar surface, wherein: the spatially connected biological sample comprises a tissue sample, the tissue sample comprises a plurality of cells, the planar surface comprises glass, plastic, or a combination thereof, the planar surface further comprises a plurality of binding sites, the plurality of binding sites is arranged in a two-dimensional pattern on the planar surface, the planar surface comprises at least 10⁵ binding sites, each of the plurality of binding sites comprises a plurality of single-stranded oligonucleotides, and the plurality of single-stranded oligonucleotides is coupled to the planar surface.at least one subset of the plurality of single-stranded oligonucleotides comprises: (i) a binding sequence comprising a plurality of thymine bases configured to bind to poly-A sequences, (ii) a unique molecular identifier, (iii) a barcode associated with a position on the planar surface, and (iv) a sequencing primer, and each oligonucleotide of the subset of the plurality of single-stranded oligonucleotides comprises at least 50 nucleotides; (b) imaging at least a portion of the spatially linked biological sample, wherein the imaging comprises bright-field imaging, phase-contrast imaging, fluorescence imaging, or a combination thereof; (c) releasing nucleic acids from the spatially linked biological sample; and (d) capturing at least one subset of the nucleic acids on at least the subset of single-stranded oligonucleotides, thereby recovering the captured nucleic acids.the captured nucleic acids are immobilized on the flat surface.

The invention provides a method for detecting mycotoxin by using a carbon nanotube field effect transistor biosensor based on nucleic acid conformation change, which comprises the following steps: anchoring a modified nucleic acid aptamer on the surface of an ion shielding gold film layer through a gold-sulfur bond by using a CNT-FET biosensor with an ion shielding gold film layer above a channel to construct a sensing interface; the modified nucleic acid aptamer consists of a target mycotoxin original nucleic acid aptamer sequence and an oligomeric thymine deoxynucleotide fragment directionally inserted into the 5'end of the target mycotoxin original nucleic acid aptamer sequence; during detection, mycotoxin in a to-be-detected sample is specifically combined with the modified nucleic acid aptamer, secondary conformation change of the mycotoxin close to the gold film layer is triggered, the CNT-FET biosensor converts an electric field effect caused by conformation displacement into a channel carrier concentration change signal, and quantitative detection is achieved according to the linear relation between the signal and the mycotoxin concentration. According to the method, the nucleic acid aptamer is directionally modified, so that the electrical response after the low-charge-quantity / electrically neutral mycotoxin is combined with the sensor is enhanced, and the detection sensitivity is greatly improved.

The invention discloses a detection method for nucleoside components of cuttlebone medicinal materials, decoction pieces, standard decoction or formula granules and application of the detection method, and relates to the technical field of traditional Chinese medicine identification. The detection method for nucleoside components in cuttlebone medicinal materials, decoction pieces, standard decoction or formula granules comprises the following steps: extracting cuttlebone medicinal materials, decoction pieces, standard decoction or formula granules by adopting an extraction solvent to obtain a test solution; dissolving or extracting a reference substance and / or a cuttlebone reference medicinal material by adopting an extraction solvent to obtain a reference substance solution and / or a reference medicinal material solution; determining the test solution, the reference substance solution and / or the reference medicinal material solution by adopting a liquid chromatograph; wherein a chromatographic column of the liquid chromatograph takes octadecylsilane chemically bonded silica as a stationary phase, methanol as a mobile phase A and water as a mobile phase B for gradient elution, and the reference substances comprise a uracil reference substance, a cytidine reference substance, a hypoxanthine reference substance, a thymine reference substance, a guanosine reference substance and an adenosine reference substance; the extraction solvent is water or a methanol aqueous solution with the concentration of 10-30 vol%. The detection method disclosed by the invention can be used for determining various nucleoside components in the cuttlebone, effectively identifying common counterfeit products and providing a scientific basis for formulating a quality standard of the cuttlebone.

The present invention belongs to the field of recombinant microbial technology, and specifically relates to a recombinant bacterial strain and a method for producing amino acids therefrom. The present invention provides a waaA mutation, wherein the waaA mutation results in an amino acid change in the catalytic region of the protein encoded by waaA, specifically a mutation of the proline at position 48 of the protein sequence encoded by waaA to a hydroxyl-containing amino acid, or a mutation of the nucleotide sequence of waaA where the nucleotide at position 142 is replaced by cytosine to thymine or adenine. The recombinant strain containing the waaA mutation provided by the present invention has the ability to produce high levels of threonine or isoleucine.

The present application relates to the technical field of medicine, and in particular to a nonionic gene vector on the basis of a hydrogen bond donor group, and a preparation method therefor and the use thereof. The gene vector loads a gene drug via a group that functions as a hydrogen bond and is formed by a hydrogen bond donor gene and a gene nucleoside or phosphate, and comprises a hydrogen bond donor group being a nonionic lipid and a hydrogen bond donor nonionic polymer. The hydrogen bond donor group mainly comprises thiourea, polyphenol, hydroxyl, urea, thymine, uracil, cytosine, adenine and guanine. The delivery system of the present application can be easily prepared, and loading can be achieved by means of a simple method of blending with mRNA at room temperature, which avoids the previous problems, such as the complex preparation process. In addition, the delivery system of the present invention has the characteristic of being degradable and has good biosafety.

The invention discloses a mutant gene enrichment method, a mutant gene detection method and a mutant gene detection kit based on Cas9 specific cleavage and isonucleotide magnetic beads. The method comprises the following steps: firstly, extracting free DNA; then identifying and cutting a completely matched wild type sequence by using Cas9 protein and specific sgRNA, and reserving the mutant DNA due to base mismatch; cas9 treated DNA and streptavidin magnetic beads containing a biotinylated oligonucleotide probe are incubated, guanine and cytosine in the probe are substituted by isoguanine and isocytosine respectively, and adenine and thymine are modified by locked nucleic acid, so that high-stability homodromous pairing is realized, and mutation DNA is selectively enriched; and finally, carrying out qPCR or sequencing detection on the enriched DNA. The kit has the characteristics of simplicity and convenience in operation, high specificity and high sensitivity, can be used for detecting single-base-level mutation, and is suitable for liquid biopsy, tumor early screening and genetic disease mutation detection.

The invention discloses a QPCR (Quantitative Polymerase Chain Reaction)-based DNA (Deoxyribose Nucleic Acid) methylation rate detection method, which comprises the following steps of: treating a DNA sample to be detected by bisulfite, dividing the DNA sample into a first sample and a second sample which are parallel to each other, and performing substrate amplification on a methylated DNA template and a non-methylated DNA template in the samples through PCR amplification by adopting the same amplification primer under the same condition; then respectively depleting dATP in a sample A reaction system and dGTP in a sample B reaction system through a template and a primer with thymine deoxyribonucleotide repetitive sequences or a template and a primer with cytosine deoxyribonucleotide repetitive sequences, and controlling independent detection of methylation and non-methylation templates through a d3TP system lacking dATP or dGTP; and finally, directly analyzing the fluorescence signal of the methylation template and the fluorescence signal of the non-methylation template, and calculating the methylation rate of the DNA sample to be detected through a methylation rate calculation function.

A pharmaceutical combination comprising a thymine DNA glycosylase (TDG) inhibitor and an immune checkpoint inhibitor, and the use thereof in the preparation of a drug for preventing, alleviating, and / or treating related diseases containing a TP53 gene mutation, such as tumors.

The invention relates to high-purity thymine, a process of purification of thymine, a process for preparing high-purity deoxythymidine, pharmaceutical compositions containing high-purity deoxythymidine and deoxycytidine as well as their use as pharmaceuticals for treatment of mitochondrial depletion syndromes in a mammal.

The invention discloses an enzyme composition, an immobilized enzyme and application. The enzyme composition consists of uridine phosphorylase and thymine phosphorylase. The enzyme composition and the immobilized enzyme are simple to prepare, have the characteristics of high conversion efficiency, high yield and simplicity and convenience in operation when being used for synthesizing 2 '-fluoro-2'-deoxycytidine, and can effectively reduce the production cost. Meanwhile, synthetic reaction conditions of the 2 '-fluoro-2'-deoxycytidine based on the enzyme composition and the immobilized enzyme are mild, green and environment-friendly, and the environmental problem caused by chemical synthesis can be avoided.

Disclosed is the use of a PNcgl1969(C200T) promoter and a biomaterial related thereto in the construction of a high-yield L-lysine engineered strain. The promoter is a DNA molecule obtained by means of mutating cytosine at position 200 in the PNcgl1969 promoter to thymine. By means of performing L-lysine fermentation experiments on the constructed engineered strains L-PNcgl1969 and Y-PNcgl1969 containing the PNcgl1969(C200T) promoter, it is found that a point mutation of the PNcgl1969 promoter region in Corynebacterium glutamicum is conducive to improving the yield of L-lysine. The present invention is of great significance for increasing the yield of L-lysine produced by means of bacterial fermentation.

Protein complexes including a cytidine deaminase and a helicase. In some embodiments, the cytidine deaminase is an altered cytidine deaminase. In some embodiments, the protein complex converts 5 methylcytosine to thymine. Kits, compositions, and methods of use for the protein complexes including a cytidine deaminase and a helicase are also described.

The invention includes improved methods and compositions for detecting methylation in nucleic acids. In particular, the disclosure is directed to methods of converting 5-hydroxymethylcytosine (5hmC) and / or 5-methylcytosine (5mC) to Thymine (T). In addition, the disclosure is also directed to methods of detecting 5hmC and / or 5mC in a sample.

The invention provides a yarrowia lipolytica adaptive evolution vector as well as a construction method and application thereof. The vector comprises a fusion expression unit containing a yarrowia lipolytica source dnaB helicase gene and a cytidine deaminase gene human source rAPOBEC1, an escherichia coli resistance gene segment AmpR, a URA selection marker, a yarrowia lipolytica autonomous replication sequence ARS / CEN, a promoter UAS1B8-tef and a plasmid replication origin ori. The vector can efficiently and quickly mutate cytosine at any site on a yarrowia lipolytica genome into thymine, and amino acid mutation or gene inactivation can be realized. The carrier is used for domesticating the yarrowia lipolytica under various conditions, so that the growth performance of the yarrowia lipolytica under corresponding culture conditions can be quickly and remarkably improved, and the evolution cycle is shortened.

The disclosed technology relates to a method of analyzing DNA from a biological sample. In one aspect, the method comprises obtaining a sample a sample from a subject, the sample comprising DNA that comprises double-stranded DNA (dsDNA) suspected of having one or more thymine lesions formed by deamination of 5-methylcytosines, wherein the thymine lesions form base pair mismatches in the dsDNA, contacting the sample with a nuclease that digests dsDNA at base pair mismatches; harvesting DNA from the nuclease-treated sample; and performing an analysis on undigested DNA harvested from the nuclease-treated sample.